Assays of von Willebrand Factor- Cleaving Protease: A Test for Diagnosis of Familial and Acquired Thrombotic Thrombocytopenic Purpura

ABSTRACT

Endothelial cells secrete von Willebrand factor (vWF) multimers that are larger than those found in the circulating plasma. These very large multimeric forms of vWF, capable of spontaneously binding to and agglutinating the blood platelets under conditions of high fluid shear rate, are degraded by a specific metalloprotease cleaving the peptide bond 842Tyr-843Met of the vWF subunit. The vWF-cleaving protease was found to be deficient in patients with familial thrombotic thrombocytopenic purpura (TTP). The acute events in these patients can be successfully treated and prophylactically prevented by repletion of the missing protease using fresh frozen plasma (FFP). In another, apparently more common, form of TTP, the protease deficiency is due to inhibiting circulating antibodies directed against the vWF-cleaving protease. Therapy of these patients should include immunosuppressive treatment in addition to plasma exchange and replacement with FFP. Normal activity of vWF-cleaving protease was established in patients with a clinically similar disorder: hemolytic-uremic syndrome (HUS). The level of vWF-cleaving protease activity is thus a laboratory parameter that provides important information for the differential diagnosis and treatment of patients with TTP/HUS. Several assays of vWF-cleaving protease have been described and are summarized here.

KEYWORDS

TTP - HUS - von Willebrand factor - vWF-cleaving protease - assay

REFERENCES

• 1 Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura.  Eur J Haematol . 1996;  56 191-207
• 2 Moake J L, Chow T W. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare.  Am J Med Sci . 1998;  316 105-119
• 3 Thompson C E, Damon L E, Ries C A, Linker C A. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.  Blood . 1992;  80 1890-1895
• 4 Hellman R M, Jackson D V, Buss D H. Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome in HLA-identical siblings.  Ann Intern Med . 1980;  93 283-284
• 5 Elias M, Horowitz J, Tal I, Kohn D, Flatau E. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in three siblings.  Arch Dis Child . 1988;  63 644-646
• 6 Ruggenenti P, Remuzzi G, Rossi E C. Epidemiology of the hemolytic uremic syndrome.  N Engl J Med . 1991;  324 1065-1066
• 7 Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy.  Baillieres Clin Haematol . 1998;  11 475-495
• 8 Kwaan H C. Clinicopathologic features of thrombotic thrombocytopenic purpura.  Semin Hematol . 1987;  24 71-81
• 9 Siddiqui F A, Lian EC-Y. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.  J Clin Invest . 1985;  76 1330-1337
• 10 Chen S, Lian EC-Y. Purification and some properties of a 59 kDa platelet aggregating protein from the plasma of a patient with thrombotic thrombocytopenic purpura.  Blood (Abst) . 1988;  72 318a
• 11 Murphy W G, Moore J C, Kelton J G. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura.  Blood . 1987;  70 1683-1687
• 12 Kelton J G, Warkentin T E, Hayward C PM, Murphy W G, Moore J C. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles.  Blood . 1992;  80 2246-2251
• 13 Moore J C, Murphy W G, Kelton J G. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura.  Br J Haematol . 1990;  74 457-464
• 14 Schultz D R, Arnold P I, Jy W. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen.  Br J Haematol . 1998;  101 849-857
• 15 Laurence J, Mitra D, Steiner M, Staiano-Coico X, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells.  Blood . 1996;  87 3245-3454
• 16 Moake J L, Rudy C K, Troll J H. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med . 1982;  307 1432-1435
• 17 Tsai H M, Nagel R L, Hatcher V B, Sussman I I. Multimeric composition of endothelial cell-derived von Willebrand factor.  Blood . 1989;  73 2074-2076
• 18 Zimmerman T S, Dent J A, Ruggeri Z M, Nannini L H. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).  J Clin Invest . 1986;  77 947-951
• 19 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.  J Clin Invest . 1991;  88 774-777
• 20 Dent J A, Berkowitz S D, Ware J, Kasper C K, Ruggeri Z M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease.  Proc Natl Acad Sci USA . 1990;  87 6306-6310
• 21 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood . 1996;  87 4223-4234
• 22 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ions.  Blood . 1996;  87 4235-4244
• 23 Furlan M, Robles R, Solenthaler M. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood . 1997;  89 3097-3103
• 24 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost . 1999;  81 8-13
• 25 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood . 1998;  91 2839-2846
• 26 Furlan M, Robles R, Galbusera M. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med . 1998;  339 1578-1584
• 27 Tsai H M, Lian E CY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med . 1998;  339 1585-1594
• 28 Elliott M A, Daniels T M, Owen W G, Nichols W L. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): a simplified laboratory assessment of von Willebrand factor-cleaving protease (vWF-CP) activity.  Blood (Abst) . 1999;  94(Suppl 1) 14a
• 29 Tsai H M, Sussman I I, Nagel R L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.  Blood . 1994;  83 2171-2179
• 30 Gerritsen H, Turecek P, Schwarz H P, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).  Thromb Haemost . 1999;  82 1386-1389
• 31 Aronson D L, Kricek D M, Rick M. A collagen binding assay for quantitating the proteolysis of von Willebrand factor.  Blood (Abst) . 1999;  94(Suppl 1) 85b
• 32 Loof A H, Van Vliet H D M H, Kappers-Klunne M. Quantification of the activity of a von Willebrand factor proteolysing metalloprotease using collagen binding affinity, during a plasmapheresis episode of three patients suffering from thrombotic thrombocytopenic purpura.  Blood (Abst) . 1999;  94(Suppl 1) 81b
• 33 Obert B, Tout H, Veyradier A. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.  Thromb Haemost . 1999;  82 1382-1385